Contrave is a drug owned by Nalpropion Pharmaceuticals Llc. It is protected by 22 US drug patents filed from 2014 to 2024. Out of these, 19 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 02, 2034. Details of Contrave's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10835527 | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(9 years from now) | Active |
| US10231964 | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(9 years from now) | Active |
| US11998542 | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(9 years from now) | Active |
| US10828294 | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(9 years from now) | Active |
| US9633575 | Methods of treating overweight and obesity |
Jun, 2033
(8 years from now) | Active |
| US11139056 | Methods of treating overweight and obesity |
Jun, 2033
(8 years from now) | Active |
| US10403170 | Methods of treating overweight and obesity |
Jun, 2033
(8 years from now) | Active |
| US9248123 | Methods of providing weight loss therapy in patients with major depression |
Jan, 2032
(7 years from now) | Active |
| US11033543 | Methods of providing weight loss therapy in patients with major depression |
Jan, 2031
(6 years from now) | Active |
| US8916195 | Sustained release formulation of naltrexone |
Feb, 2030
(5 years from now) | Active |
| US11324741 | Methods for treating visceral fat conditions |
May, 2029
(4 years from now) | Active |
| US8088786 | Layered pharmaceutical formulations |
Feb, 2029
(4 years from now) | Active |
| US8722085 | Methods for administering weight loss medications |
Nov, 2027
(2 years from now) | Active |
| US12048769 | Methods for administering weight loss medications |
Nov, 2027
(2 years from now) | Active |
| US8318788 | Layered pharmaceutical formulations |
Nov, 2027
(2 years from now) | Active |
| US9125868 | Methods for administering weight loss medications |
Nov, 2027
(2 years from now) | Active |
| US10307376 | Methods for administering weight loss medications |
Nov, 2027
(2 years from now) | Active |
| US9107837 | Sustained release formulation of naltrexone |
Jun, 2027
(2 years from now) | Active |
| US7375111 | Compositions for affecting weight loss |
Mar, 2025
(3 months from now) | Active |
| US8815889 | Compositions and methods for increasing insulin sensitivity |
Jul, 2024
(4 months ago) |
Expired
|
| US7462626 | Compositions for affecting weight loss |
Jul, 2024
(4 months ago) |
Expired
|
| US11278544 | Compositions for affecting weight loss |
Apr, 2024
(7 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Contrave's patents.
Latest Legal Activities on Contrave's Patents
Given below is the list of recent legal activities going on the following patents of Contrave.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 15 May, 2024 | US8318788 (Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 May, 2024 | US10835527 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 24 Apr, 2024 | US10828294 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 19 Jul, 2023 | US9248123 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 21 Jun, 2023 | US8088786 (Litigated) |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 22 Feb, 2023 | US9125868 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Feb, 2023 | US10403170 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 01 Feb, 2023 | US9107837 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 09 Jan, 2023 | US9125868 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 16 Nov, 2022 | US10307376 |
FDA has granted several exclusivities to Contrave. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Contrave, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Contrave.
Exclusivity Information
Contrave holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Contrave's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
US patents provide insights into the exclusivity only within the United States, but Contrave is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Contrave's family patents as well as insights into ongoing legal events on those patents.
Contrave's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Contrave's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 02, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Contrave Generics:
There are no approved generic versions for Contrave as of now.
How can I launch a generic of Contrave before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Contrave's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Contrave's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Contrave -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 8 mg/90 mg | 12 Mar, 2015 | 1 | 02 Feb, 2030 |
About Contrave
Contrave is a drug owned by Nalpropion Pharmaceuticals Llc. It is used for chronic weight management and treating overweight or obesity, as well as to address blood glucose parameters and major depressive disorder in patients. Contrave uses Bupropion Hydrochloride; Naltrexone Hydrochloride as an active ingredient. Contrave was launched by Nalpropion in 2014.
Approval Date:
Contrave was approved by FDA for market use on 10 September, 2014.
Active Ingredient:
Contrave uses Bupropion Hydrochloride; Naltrexone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Bupropion Hydrochloride; Naltrexone Hydrochloride ingredient
Treatment:
Contrave is used for chronic weight management and treating overweight or obesity, as well as to address blood glucose parameters and major depressive disorder in patients.
Dosage:
Contrave is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 90MG;8MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |